Pulse Biosciences, Inc.

NASDAQ:PLSE

Medical - Instruments & Supplies

Healthcare
$45.83 +3.83%

+$0.97 today

Market cap
$3.37B
Beta
1.66
P/E (TTM)
-24.0
EPS (TTM)
-$1.10
52W Low $12.56High $28.53

Volume 0.33M

Average 0.31M

PLSE Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Pulse Biosciences, Inc.NASDAQ: PLSE

Net Change in Cash · Q2 FY2026 · quarter ended Jun 2026

Net change in cash turns positive

Q2 FY2026 net change in cash was $33.3M, compared with -$12.93M a year earlier. Trailing-twelve-month net change in cash was -$4.73M.

Context

  • Net change in cash amounted to 10658.0% of revenue in FY2025.
  • Net change in cash increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly net change in cash holds near $33.3M or moves back toward the trailing-twelve-month quarterly average of -$1.18M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$33.3M+368.2% QoQ
Last fiscal yearDec 2025
-$37.3M-150.6% YoY
LTMJun 2026
-$4.73M-105.9% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+357.5%——
1 year-150.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
(37.3M) USD
Year-over-year change
-150.6%

Net Change in Cash vs competitors

How PLSE compares with its peers on the latest reported figures

  • Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -105.9% is the 9th highest of 11, against a peer median of -8.9%.
  • Net change in cash amounts to 399.1% of revenue for PLSE, versus a peer median of 22.0%.
PLSE Competitors
Net Change in Cash for PLSE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KMTSKestra Medical Technologies, Ltd.LTM Jan 2026$236.97M USD+504.0%—283.0%
ATAIAtai Beckley Inc.LTM Jun 2026$106.87M USD+287.1%—2389.2%
DNTHDianthus Therapeutics, Inc.LTM Jun 2026$97.25M USD+132.3%+53.6%5107.6%
OPKOPKO Health, Inc.LTM Mar 2026$94.11M USD-125.2%—16.2%
IMTXImmatics N.V.LTM Mar 2026€51.59M EUR-57.3%+106.7%138.3%
STAASTAAR Surgical CompanyLTM Apr 2026$41.25M USD-19.0%—14.2%
NVCRNovoCure LimitedLTM Mar 2026$32.11M USD-90.2%-12.6%4.8%
NKTRNektar TherapeuticsLTM Jun 2026$15.21M USD+1.2%—27.9%
BBNXBeta Bionics, Inc.LTM Mar 2026$12.25M USD-136.7%—11.1%
PLSEPulse Biosciences, Inc.LTM Jun 2026$4.73M USD-105.9%—399.1%
LFMDLifeMD, Inc.LTM Mar 2026$84.73K USD+111.8%—0.0%
Peer median (excluding PLSE) —-8.9%+53.6%22.0%

Competitors are the stored peer set for PLSE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(63.66M)(58.51M)(42.21M)(53.59M)(72.78M)
Depreciation & Amortization1.15M1.36M1.21M1.18M1.07M
Deferred Income Tax00000
Stock-Based Compensation14.6M5.19M7.18M13.59M21.46M
Change in Working Capital(6.2M)(3.72M)768K2.47M(5.02M)
Accounts Receivables(61K)20K109K48K(274K)
Inventory(5.82M)(2.65M)00(136K)
Accounts Payables1.16M(1.3M)263K(201K)1.13M
Other Working Capital(1.47M)221K396K2.63M(5.74M)
Other Non-Cash Items13K8.66M13K6K1.15M
Operating Cash Flow(54.1M)(47.01M)(33.04M)(36.34M)(54.12M)
Capital Expenditures(437K)(401K)(121K)(125K)(315K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments8M0000
Other Investing Activities0000(20K)
Investing Cash Flow7.56M(401K)(121K)(125K)(335K)
Debt Repayment407K65M000
Common Stock Issued56.7M14.86M16.39M59.65M17.15M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities62.51M75K(6K)50.49M0
Financing Cash Flow62.69M79.94M16.39M110.14M17.15M
Effect of Forex Changes00000
Net Change in Cash16.15M32.53M(16.77M)73.67M(37.3M)
Free Cash Flow(54.53M)(47.41M)(33.16M)(36.47M)(54.44M)

Pulse Biosciences, Inc.

NASDAQ:PLSE

Intrinsic Alpha fair value

Locked

Current Price

$45.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.